J.D., University of Maryland School of Law with honors
Ph.D., Developmental Biology, The Johns Hopkins University
M.S., Cell Biology, University of Michigan
B.S., Plant Biology, Duke University cum laude
District of Columbia
United States Patent and Trademark Office
Dr. Hoover, a Director in the Biotechnology/Chemical Group, has firsthand understanding of his clients’ intellectual property and business needs and how they are impacted by an increasingly competitive marketplace. His practice focuses on the strategic evaluation, creation, protection, and leveraging of IP assets. He specializes in corporate intellectual property and provides counsel on matters relating to: product driven portfolio, lifecycle, and risk management; IP asset transfer and licensing; preparing for, conducting, and defending IP-related due diligence inquiries; and patentability, freedom to operate, validity, and infringement issues. Dr. Hoover also has extensive domestic and foreign patent prosecution experience and has prosecuted nearly 500 U.S. patents to issuance, alone.
Dr. Hoover routinely advises life science companies from nascent technology-based startup innovators to large, established biopharmaceutical companies, on the impact of IP on business and ways to better align IP portfolios, strategies, and expenses with near term and long term strategic corporate goals. He also counsels on IP matters relating to all phases and aspects of biopharmaceutical development, from early research and development, through clinical trials, and commercialization.
Dr. Hoover's knowledge and experience provide him with a unique combination of technical and commercial expertise in the areas of: oncology; infectious disease; diseases, and disorders of the immune system; therapeutic antibodies and alternative scaffolds; and drug discovery and development platforms. He also has extensive research and commercial-based technical proficiency in the areas of: agricultural and industrial biotechnology, plant, insect and animal genetics, genetic engineering, and molecular and cellular biology; plant and animal growth and developmental biology; biochemistry; microbiology; immunology; diagnostics; and biologics. Dr. Hoover’s doctoral research studied mechanisms of transcriptional regulation.
Prior to joining Sterne Kessler, Dr. Hoover spent 11 years at Human Genome Sciences Inc., in the Intellectual Property, Legal, and Business Development departments, where he held positions including Associate General Counsel, Intellectual Property; Executive Director of Technology Assessment and Licensing; and Executive Director of Scientific Assessment. He led HGSI’s intellectual property group and the company’s evaluation of internal and external opportunities and licensing efforts. Dr. Hoover was an integral member of HGSI’s cross-departmental teams responsible for initially characterizing BLyS (aka, BAFF and TNFSF13b) and many of the company’s lead targets, and for developing and shepherding drugs directed against these targets through clinical trials. Dr. Hoover also prosecuted HGSI’s seminal patents relating to BENLYSTA® (belimumab).
Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler. If you are not already a client of Sterne Kessler, do not include any confidential information in this message.